Icon Plc Dossier
Qualitative Analysis
Business overview
ICON plc (NASDAQ: ICLR) is a premier global contract research organization (CRO) headquartered in Dublin, Ireland. The company provides a comprehensive suite of outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. ICON specializes in the strategic development, management, and analysis of clinical programs across all phases of drug development (Phases I-IV). Following its transformative acquisition of PRA Health Sciences in 2021, ICON has established itself as one of the largest global CROs, operating with a workforce of approximately 40,100 employees across more than 50 countries.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Strategic initiatives designed to strengthen ICON's competitive position and capitalize on emerging opportunities, focusing on digital innovation and operational efficiency.
Expected impact: Designed to strengthen ICON's competitive position and capitalize on emerging opportunities.
Opening of a new, state-of-the-art 69,500 sq ft Clinical Research Unit (CRU) in San Antonio, Texas, alongside new satellite outpatient clinics in Houston, Texas and Lawrence, Kansas.
Expected impact: Significantly increases U.S. capacity to conduct first-in-human, healthy participant, and patient cohort studies by co-locating clinical, laboratory, and pharmacy operations under one roof to eliminate logistical delays.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of a mid-sized contract research organization (CRO) offering full-service and functional services partnership (FSP) clinical trial services, primarily focused on biotech sponsors.
Financial impact: Resulted in the final recognition of $43.4 million in goodwill and $45.1 million in intangible assets.
Acquisition of a cloud-based technology company for life sciences supporting precision measurement in patient-centered clinical research.
Financial impact: Resulted in the initial recognition of $2.7 million in goodwill and $9.9 million in developed technology intangible assets.
Strategic Partnerships
Introduces a new 'research-ready,' connected site network model for clinical trials. Integrates ICON's global clinical trial solutions with Advarra's site CTMSs, eISF, and eSource systems to reduce administrative friction, accelerate study startup, and leverage Advarra's Braid data and AI platform for deep operational intelligence.
Terms: Not disclosed